Indonesia has approved the Covid-19 vaccine of China’s Sinopharm on this Friday, which it will use in a private immunization scheme where companies buy government-procured vaccines to inoculate their staff.
After Sinovac Biotech and AstraZeneca, Sinopharm is the third company to have its vaccine approved by Indonesia, which is seeking to inoculate 181.5 million people by January 2022.
Verdi Budidarmo, CEO of pharmaceutical company Kimia Farma which distributes the vaccine, said that the private vaccination program, which starts next month, is expected to back up the government to reach herd immunity in Indonesia.
Indonesia’s vaccine program has slowed due to an export ban from India and other supply issues, although health minister Budi Gunadi Sadikin said he hoped it could get back on track in May. So far, it has administered at least one shot of Covid-19 vaccine to about 12.3 million of its 270 million population
After Sinovac Biotech and AstraZeneca, Sinopharm is the third company to have its vaccine approved by Indonesia, which is seeking to inoculate 181.5 million people by January 2022.
Verdi Budidarmo, CEO of pharmaceutical company Kimia Farma which distributes the vaccine, said that the private vaccination program, which starts next month, is expected to back up the government to reach herd immunity in Indonesia.
Indonesia’s vaccine program has slowed due to an export ban from India and other supply issues, although health minister Budi Gunadi Sadikin said he hoped it could get back on track in May. So far, it has administered at least one shot of Covid-19 vaccine to about 12.3 million of its 270 million population
